actamrapprovalsaxelsenbayhbigbillbiotechcapitalcareceochallengeschinacompetitioncongresscontrolscurescutsdealdebatedevelopmentdoledrugequityfalloutfdafutureglobalglphealthhealthcareimpactindustryinflationinnovationinsideinvestmentipjpmkirstenleadershiplifelivemfnnextorphanoutlookpasspatientspharmapoliciespolicypresspricepricingreductionreshapingreviewsbirsciencesshutdownsmallsurgetariffstrumpvc